Development of SV2A Ligands for Epilepsy Treatment: A Review of Levetiracetam, Brivaracetam, and Padsevonil
文献类型：期刊论文
| 作者 | Wu, Peng-Peng2,3; Cao, Bi-Rong2,3; Tian, Fu-Yun1,3; Gao, Zhao-Bing1,2,3
|
| 刊名 | NEUROSCIENCE BULLETIN
 |
| 出版日期 | 2023-10-28 |
| 页码 | 15 |
| 关键词 | Levetiracetam Epilepsy Antiseizure medications Synaptic vesicle protein 2A Brivaracetam Padsevonil |
| ISSN号 | 1673-7067 |
| DOI | 10.1007/s12264-023-01138-2 |
| 通讯作者 | Tian, Fu-Yun(tianfuyun@zidd.ac.cn) ; Gao, Zhao-Bing(zbgao@simm.ac.cn) |
| 英文摘要 | Epilepsy is a common neurological disorder that is primarily treated with antiseizure medications (ASMs). Although dozens of ASMs are available in the clinic, approximately 30% of epileptic patients have medically refractory seizures; other limitations in most traditional ASMs include poor tolerability and drug-drug interactions. Therefore, there is an urgent need to develop alternative ASMs. Levetiracetam (LEV) is a first-line ASM that is well tolerated, has promising efficacy, and has little drug-drug interaction. Although it is widely accepted that LEV acts through a unique therapeutic target synaptic vesicle protein (SV) 2A, the molecular basis of its action remains unknown. Even so, the next-generation SV2A ligands against epilepsy based on the structure of LEV have achieved clinical success. This review highlights the research and development (R&D) process of LEV and its analogs, brivaracetam and padsevonil, to provide ideas and experience for the R&D of novel ASMs. |
| WOS关键词 | SYNAPTIC VESICLE PROTEIN ; PLACEBO-CONTROLLED TRIAL ; PARTIAL-ONSET SEIZURES ; ADD-ON THERAPY ; MULTICENTER DOUBLE-BLIND ; ANTIEPILEPTIC DRUG ; ADJUNCTIVE BRIVARACETAM ; ANTICONVULSANT DRUG ; UCB L059 ; BINDING CHARACTERISTICS |
| 资助项目 | This review was supported by funding from the High-level New Ramp;D Institute (2019B090904008) and the High-level Innovative Research Institute (2021B0909050003) of the Department of Science and Technology of Guangdong Province, National Science and Techn[2019B090904008] ; High-level New Ramp;D Institute[2021B0909050003] ; High-level Innovative Research Institute[2021ZD0200900] ; Department of Science and Technology of Guangdong Province[2018SHZDZX05] ; Shanghai Municipal Science and Technology Major Project[210724194041939] ; Zhongshan Municipal Bureau of Science and Technology[81825021] ; National Science Fund for Distinguished Young Scholars |
| WOS研究方向 | Neurosciences & Neurology |
| 语种 | 英语 |
| WOS记录号 | WOS:001088798300001 |
| 出版者 | SPRINGER |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/307569]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Tian, Fu-Yun; Gao, Zhao-Bing |
| 作者单位 | 1.Chinese Acad Sci, Zhongshan Inst Drug Discovery, Shanghai Inst Mat Med, Zhongshan 528400, Peoples R China 2.Univ Chinese Acad Sci, Beijing 100049, Peoples R China 3.Chinese Acad Sci, Ctr Neurol & Psychiat Res & Drug Discovery, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China |
| 推荐引用方式 GB/T 7714 | Wu, Peng-Peng,Cao, Bi-Rong,Tian, Fu-Yun,et al. Development of SV2A Ligands for Epilepsy Treatment: A Review of Levetiracetam, Brivaracetam, and Padsevonil[J]. NEUROSCIENCE BULLETIN,2023:15. |
| APA | Wu, Peng-Peng,Cao, Bi-Rong,Tian, Fu-Yun,&Gao, Zhao-Bing.(2023).Development of SV2A Ligands for Epilepsy Treatment: A Review of Levetiracetam, Brivaracetam, and Padsevonil.NEUROSCIENCE BULLETIN,15. |
| MLA | Wu, Peng-Peng,et al."Development of SV2A Ligands for Epilepsy Treatment: A Review of Levetiracetam, Brivaracetam, and Padsevonil".NEUROSCIENCE BULLETIN (2023):15. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。